CartalaX 20mg 10vials
$130.00
Cartalax is a synthetic tripeptide (Ala-Glu-Asp) bioregulator that targets chondrocyte nuclei to epigenetically upregulate Type II collagen and proteoglycan synthesis. It promotes articular cartilage repair and synovial homeostasis for joint health research.
100% delivery
- Satisfaction Guaranteed
- No Hassle Refunds
- Secure Payments
Description
Cartalax Cartilage Peptide Bioregulator for Joint Health Research
Mechanism Overview
The biochemical activity of Cartalax is defined by its ability to penetrate the cellular membrane and interact with the epigenetic machinery of chondrocytes. The primary mechanism involves the tripeptide sequence enters the nucleus and binds to specific segments of DNA, modulating methylation patterns in the promoter regions of structural genes. This defines the first semantic triple: [Cartalax modulates DNA methylation]. Secondly, this epigenetic interaction facilitates the unwrapping of condensed chromatin, allowing for the up-regulation of genes responsible for the synthesis of Type II collagen and proteoglycans. This establishes the second triple: [Ala-Glu-Asp activates chondrocyte protein synthesis]. Thirdly, Cartalax influences the functional balance of synovial fibroblasts, preventing the excessive production of pro-inflammatory enzymes. This forms the third triple: [Cartalax regulates extracellular matrix deposition]. Quantitatively, Cartalax demonstrates a systemic half-life of approximately 50 minutes, yet its impact on protein transcription can persist for several weeks. Unlike Sigumir, which is a complex bovine-derived extract, Cartalax is a highly purified synthetic analog that ensures precise dosing and immediate biological availability in laboratory assays.
Product Specifications
- CAS Number: 141613-27-4
- Molecular Formula: C11H17N3O7
- Molecular Weight: 303.27 Da
- Purity: >99.0% via HPLC-UV and Mass Spectrometry
- Appearance: Fine white sterile lyophilizate
Reported Findings
- Enhanced Articular Resilience: Users report significant improvements in joint load tolerance and recovery following mechanical stress.
- Resolution of Connective Stiffness: Experimental findings suggest a marked reduction in morning joint rigidity and improved range of motion in chronic research models.
- Optimized Synovial Homeostasis: According to research documentation, research shows a stabilization of synovial fluid viscosity and a reduction in biomarkers of cartilage degradation.
- Structural Collagen Density: Cross-study analysis suggests improved thickness of the articular cartilage layer in long-term observational studies.
- Anti-Inflammatory Modulation: Research models have noted a decrease in the localized expression of interleukins and metalloproteinases (MMPs) within joint capsules.
About This Compound
Cartalax is a synthetic short-chain peptide bioregulator (Alanyl-Glutamyl-Aspartic Acid) belonging to the cytogen class, specifically engineered to modulate the metabolic and regenerative pathways of cartilage tissue. This signaling molecule serves as a high-fidelity tool for researchers investigating the restoration of connective tissue homeostasis and the molecular triggers of chondrogenesis.
Key Points:
Cartalax represents a high-feasibility research tool for investigating epigenetic cartilage repair and the precise modulation of connective tissue protein synthesis.
Frequently Asked Questions
What is the half-life of Cartalax?
Cartalax has a systemic half-life of 50 minutes, though its epigenetic effects on chondrocyte protein synthesis can persist for several weeks.
How should Cartalax be stored after mixing?
Once mixed with Bacteriostatic Bac.water, the solution must be refrigerated at 2-8 degrees Celsius and used within 10 days.
Is Cartalax different from Sigumir?
Yes, Cartalax is a synthetic tripeptide (Ala-Glu-Asp), providing higher purity and more predictable research results than crude animal-derived extracts.
What is the standard research dosage for joint studies?
Experienced researchers typically use 1mg to 10mg daily for 10-30 days to evaluate cartilage protein synthesis and joint recovery.
Does Cartalax require a prescription for lab use?
Cartalax is sold strictly for laboratory research purposes and is not intended for human consumption or medical diagnosis.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.
You must be logged in to post a review.
Reviews
There are no reviews yet.